CPE Session 4. Recent Advances in the Journey to Cure Hepatitis C
|
|
- Anastasia Thornton
- 8 years ago
- Views:
Transcription
1 CPE Session 4 Recent Advances in the Journey to Cure Hepatitis C Friday, April 24, 2015 ACPE UAN L01-P 1.0 CPE Hour Jennifer Hickman, PharmD, BCACP Dr. Jennifer Hickman is an ambulatory care pharmacist in Internal Medicine at Nebraska Medicine and a clinical assistant professor at the University of Nebraska College of Pharmacy. She is a 2001 graduate of the UNMC College of Pharmacy. Jennifer has worked at the UNMC Physician s Internal Medicine clinic since 2002 with a primary focus on anticoagulation and hepatitis C. She also serves as a preceptor for fourth-year pharmacy students and PGY-1 residents in ambulatory care. She received ACCP board certifi cation in ambulatory care pharmacy (BCACP) in Jennifer lives in Omaha with her husband, Hubert, several dogs, and six children at home and scattered about at various colleges across the country. Dr. Hickman has no fi nancial interests or arrangements that would be considered a confl ict of interest for the presentation of this program. NPA 2015 Annual Convention
2 Recent Advances in the Journey to Cure Hepatitis C Jennifer Hickman, PharmD, BCACP Disclosure: I have no relevant financial relationships that would be considered a conflict of interest for the purposes of this program. This CPE program will not include discussion of non FDA approved medication use. Abbreviations HCV: Facts and Stats HCV= hepatitis C virus HCC= hepatocellular carcinoma PEG IFN= pegylated interferon RBV= ribavirin PI= protease inhibitors SVR= sustained virologic response RNA virus spread through contact with blood/body fluids Leading reason for liver transplantation in the US Initially non A, non B hepatitis until identified in late 1980 s Reliable screening test developed in 1992 Picture of human body and liver Hepatitis C in the US Screening Recommendations Reported New Cases Incidence of acute hepatitis C by year graph Estimated New and Chronic Cases New 24,700 in 2012 Chronic million High risk behavior IV or intranasal drug use Risk exposures Long term hemodialysis Needlestick or mucosal exposure to HCV infected blood Children born to HCV infected mothers Persons who have been incarcerated recipients of organ transplants or blood products Other HIV, unexplained liver disease, organ donors All persons born between CDC.gov: Division of Viral Hepatitis and National Center for HIV/AIDS, Viral Hepatitis,STD and TB Prevention 1
3 Distribution of HCV Genotypes in the US Picture of the United States Genotypes 1a and 1b account for 79% Genotype 2 accounts for 15% 2 15% 3 4 5% 1% Natural Course of Hepatitis C Acute infection Chronic infection 80% 20% ( risk if male, dx after 40 55yrs, alcohol use) 1b 21% 1a 58% Hepatocellular carcinoma 3% annual risk (1/3 of HCC is related to HCV, mostly pts with cirrhosis/advanced fibrosis) CDC.gov: Division of Viral Hepatitis and National Center for HIV/AIDS, Viral Hepatitis,STD and TB Prevention Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28: Prevalence of HCV and Complications Prevalence of HCV graph Hepatitis C Progression Progression to fibrosis graph natap.org Fibrosis & Disease Progression in Hepatitis C. Marcellin, et al. Hepatology, 2002 HCV/HIV Co Infection Economic Burden of HCV in the US* 25% of people with HIV are co infected with hepatitis C Common risk factors 80% of patients with HIV who injected drugs are co infected Liver disease is the leading cause of non AIDS related death in HIV patients More rapid progression of liver disease *Per year, per person in $2010 Liver transplant $201,000 Hepatocellular carcinoma $23 44,000 Variceal hemorrhage $25,500 Refractory ascites $24,700 Hepatic encephalopathy $16,430 Sensitive ascites $2450 Compensated cirrhosis $ Moderate chronic hepatitis C $155 Mild chronic hepatitis C $145 Picture of dollar sign FactSheet.pdf El Khoury AC, Klimack WK, Wallace C, and Razavi H. Economic burden of hepatitis C associated diseases in the United States. Journal of Viral Hepatitis, 2012; 19(3):
4 Goal of Treatment SVR (%) by Therapy SUSTAINED VIROLOGIC RESPONSE (SVR)!! Test for presence of virus 12 weeks after completion of therapy If negative, then considered CURED 99.7% will never recur/relapse Patients achieving SVR (%) IFN IFN+RBV PEG+RBV PEG+RBV+PI IFN Free Clinical trials data Cost of Medication Therapy* Economic Burden of Antiviral Therapy Acquisition Cost ($) PEG+RBV PEG+RBV+PI Harvoni Viekira+RBV Olysio+Sovaldi Cost projections estimate that treating HCV will cost the US health system $136 billion over the next 5 years!! Will account for 1 in 10 dollars spent on prescriptions Government will bear a large burden of the cost 12 35% of prison inmates have chronic HCV Treating all of the HCV patients in the VA Health System would cost nearly $12 billion even with discounted pricing!! *Genotype 1, treatment naive, non cirrhotic c sovaldi cost/ / Chhatwal J, Kanwal F, Roberts M, Dunn M. Cost Effectiveness and Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir and Ledipasvir in the United States. Annals of Internal Medicine, 2015; 162 (6): Hepatitis C Antivirals Picture of hepatitis C viral replication NS5A protein inhibitor Ledipasvir (Harvoni ) Ombitasvir (Viekira ) NS5B polymerase inhibitor Sofosbuvir (Sovaldi, Harvoni ) Dasabuvir (Viekira ) Ribavirin Unknown MOA Ritonavir (Viekira ) No activity against HCV, only used to boost paritaprevir NS3/4A protease inhibitor Paritaprevir (Viekira ) Simeprevir (Olysio ) [ f1.2.jpg] 3
5 Choice and Duration of Therapy Genotype and baseline HCV RNA quantitation Harvoni and Viekira approved for genotype 1 Previous treatment experience PEG/RBV PEG/RBV/PI Presence or absence of cirrhosis Other disease states/medications Harvoni x 12 wk Viekira+RBV x 24wk Sovaldi+Olysio+ RBV x24wk 24wk Genotype 1a Harvoni x 24wk Harvoni+RBV x 12wk Viekira +RBV x 24wk Sovaldi+Olysio+ RBV x24wk No Harvoni x 12wk Viekira +RBV x 12 wk Sovaldi+Olysio +RBV x12wk Harvoni x 12wk Viekira+RBV x 12wk Sovaldi+Olysio +RBV x12wk Genotype 1b Genotype 2 No No 24wk Harvoni x 12 wk Viekira+RBV x 12wk Sovaldi+Olysiox24wk Harvoni x 24wk Harvoni+RBV x 12wk Viekira +RBV x 12wk Sovaldi+Olysio+ RBV x24wk Harvoni x 12wk Viekira x 12 wk Sovaldi+Olysiox12wk Harvoni x 12wk Viekira x 12wk Sovaldi+Olysio +RBV x12wk Sovaldi + RBV x 16wk Sovaldi +RBV x 16wk Sovaldi + RBV + PEG IFN x 12 wk Sovaldi + RBV x 12wk Sovaldi +RBV x12wk Sovaldi + RBV + PEG IFN x 12wk + Genotype 3 Genotype 1, No cirrhosis, previous PEG/RBV/PI failure Treatment Sovaldi + RBV x 24wk Sovaldi + RBV + PEG IFN x 12wk PEG/RBV Failure Daily fixed dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) for 12 weeks is recommended for retreatment of patients without cirrhosis who have HCV genotype 1 infection, regardless of subtype, in whom a prior PEG IFN, RBV, and HCV protease inhibitor regimen has failed. 4
6 Genotype 1, with, Previous PEG/RBV/PI failure Daily fixed dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) for 24 weeks Daily fixed dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight based RBV (1000 mg [<75 kg] to 1200 mg [>75 kg]) for 12 weeks Monitoring Therapy Pre Treatment During Treatment Post Treatment HCV genotype HCV quantitation Renal function Liver enzymes Presence/absence of cirrhosis Pregnancy (ribavirin) Drug Interactions CBC, pregnancy test monthly if using RBV SCr if concern for unstable renal function Liver enzymes??? Check for sustained virologic response, 12 weeks post treatment Continued surveillance for hepatocellular carcinoma Sofosbuvir (Sovaldi ) Dosed 400mg daily with or without food Do not use if ClCr <30ml/min Most common adverse effects: fatigue, headache, nausea, and insomnia Drug interactions metabolized by P gp Avoid with inducers: phenytoin, rifampin, St. John s Wort, carbamazepine Serious (and fatal) bradycardia has occurred when using sofosbuvir/ledipasvir with amiodarone Sofosbuvir/Ledipasvir (Harvoni ) Genotype 1 ONLY!! 400mg/90mg tablet qday with/without food Adverse effects: fatigue, headache, nausea, diarrhea, insomnia Important drug interactions same as sofosbuvir AND: No amiodarone unless admitted under telemetry x 48 hrs., even if amiodarone recently stopped Digoxin increased levels No rosuvastatin Antacids 4 hrs apart If on PPI/H2RA, same time and no more than 20mg omeprazole or 40mg bid famotidine equivalent Prescribing Information: Sovaldi Prescribing Information: Harvoni Simeprevir (Olysio ) Genotype 1 only!! 150mg daily with food Only guideline recommended regimen is simeprevir, sofosbuvir + ribavirin Adverse effects: nausea, headache, fatigue, rash, photosensitivity, may cross react with sulfa allergy Interactions through CYP3A and P gp NUMEROUS including: statins, cyclosporine, macrolides, azole antifungals, antiarrhythmics, calcium channel blockers, rifampin, phenytoin, carbamazepine, digoxin Ombitasvir/Paritaprevir/Ritonavir/ Dasabuvir (Viekira ) Genotype 1 only!! Comes in daily dosing pack with instructions Adverse effects: fatigue, nausea, insomnia, rash, pruritis Drug interactions through numerous mechanisms: CYP3A and 2C8, P gp, OAT and BRCP Many drugs contraindicated including: ethinyl estradiol, gemfibrozil, simvastatin, daily sildenafil, rifampin, phenytoin, St. John s Wort, salmeterol Careful with antiarrhythmics, fluticasone, furosemide, amlodipine, cyclosporine, tacrolimus, azole antifungals, alprazolam, rosuvastatin, pravastatin Prescribing Information: Olysio Prescribing Information: Viekira 5
7 Ribavirin Used in combination therapy only 1000mg if < 75kg, 1200mg if > 75kg, in 2 divided doses Primary adverse effect is hemolytic anemia dose to 600mg if Hgb <10g/dL, stop if < 8.5 If stable CAD, to 600mg if >2g drop in Hgb and stop if Hgb < 12g/dL Do not use if ClCr < 50ml/min TERATOGENIC! Pregnancy test before treatment and monthly if childbearing potential Use 2 forms of birth control if treating male OR female during treatment and for 6 months after treatment HCV/HIV Co infection MANY potentially serious drug drug interactions between HCV and HIV medications Should be managed by or in conjunction with HIV practitioner Do NOT interrupt anti retroviral therapy to treat HCV!! After recognizing and addressing interactions, treatment options and duration should be the same as non HIV infected individuals Lexicomp Addressing Adherence 80% rule has historically been considered the standard for optimal outcomes with HCV therapy Predictors of adherence Personal connection with pharmacist/pharmacy Affordability Perceived effectiveness Simplicity of regimen Adverse effects Connectedness with a health facility Take Home Message Finally, a cure for the MAJORITY of patients with hepatitis C Opportunity to change the long term prognosis and future healthcare costs associated with chronic hepatitis C Can we afford to treat everyone? Pharmacists are well positioned to make a real impact on outcomes Medication Adherence in America, from JJ Weis, N Brau, A. Stivala, T. Swain, D. Fishbein. (2009). Adherence to medication for chronic hepatitis C building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther 30(1): Case #1 TO is a 60yowm with chronic hepatitis C, genotype 2b with cirrhosis. He previously attempted therapy with PEG/RBV but discontinued due to intolerable adverse effects. He re presents for treatment and is prescribed a 12 week course of sofosbuvir, PEG IFN, and ribavirin. Case #1: Is the prescribed therapy appropriate? a. Yes, therapy choices and duration are appropriate b. Therapy choice is appropriate, but not duration c. Duration is appropriate, but therapy is inappropriate d. Both therapy choice and duration are inappropriate What monitoring needs to be done prior to and during treatment? 6
8 Case 2: HCV Drug Drug Interactions TL is currently being treated with sofosbuvir/ledipasvir x 12 weeks for HCV genotype 1a (treatment naïve, no cirrhosis). During the course of treatment, he is diagnosed with H. Pylori. The physician prescribes Pylera *plus omeprazole 20mg bid to treat his H.Pylori and he presents these prescriptions to fill at your pharmacy. *Pylera = bismuth subcitrate potassium, metronidazole, tetracycline Case 2: HCV Drug Drug Interactions Are there any concerns with treating this patient s H.Pylori while on HCV treatment? a. No concerns, fill as prescribed b. Counsel patient to take omeprazole 4 hours apart from sofosbuvir/ledipasvir c. Omeprazole should be reduced to once daily d. Pylera should be changed to another regimen due to antibiotic interaction Case 3: The co infected patient MK is a 44 year old male who is co infected with HIV and chronic hepatitis C, genotype 1a. His current HIV regimen consists of Atripla (efavirenz/emtricitabine/tenofovir). He presents to clinic for treatment of hepatitis C. He has never been treated before and has no cirrhosis. Case 3 Which of the following is TRUE when it comes to treating MK? a. His HIV regimen will likely require adjustment b. His case should be co managed by an HIV specialist c. Treatment duration for a co infected patient is the same as for any other patient d. All of the above For more information: Questions??? hcvguidelines.org cdc.gov References: Center for Disease Control Division of Viral Hepatitis and National Center for HIV/AIDS, Viral Hepatitis,STD and TB Prevention. Hepatitis C Information for Health Professionals. Retrieved from Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology, 1998;28: Marcellin P, Asselah T, Boyer N. Fibrosis & Disease Progression in Hepatitis C. Hepatology, 2002;36(5 Suppl 1):S American Association for the Study of Liver Diseases/Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C, updated January 28, Retrieved from: El Khoury AC, Klimack WK, Wallace C, and Razavi H. Economic burden of hepatitis C associated diseases in the United States. Journal of Viral Hepatitis, 2012; 19(3): Chhatwal J, Kanwal F, Roberts M, Dunn M. Cost Effectiveness and Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir and Ledipasvir in the United States. Annals of Internal Medicine, 2015; 162 (6): Sovaldi [package insert]. Foster City, CA: Gilead Sciences; Harvoni [package insert]. Foster City, CA: Gilead Sciences; Olysio [package insert]. Titusville, NJ: Janssen Therapeutics; Viekira [package insert]. North Chicago, IL: AbbVie Inc; Lexi Comp, Inc. (Lexi Drugs); Updated 3/10/15. Medication Adherence in America: A National Report Retrieved from Weis JJ, Brau N, Stivala A, Swain T, Fishbein D. Adherence to medication for chronic hepatitis C building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther, (1): Kime, Patricia. (2015, January 28). Hepatitis C drug costing VA, DoD millions. Retrieved from c sovaldi cost/
Clinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationAn Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015. Matthew McMahon, MD
An Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015 Matthew McMahon, MD In the United States, 2.2-3.2 million people are infected with the hepatitis C virus (HCV) Half unaware
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationPHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
More informationRequest for Prior Authorization HEPATITIS C TREATMENTS
IA Medicaid Member ID # Patient name DOB FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567 Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hepatitis C Second Generation Antivirals Through Preferred
More informationHepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary
Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary This program applies to Health Insurance Marketplace, FlexRx
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following
More informationAn Update on the Treatment of Hepatitis C
An Update on the Treatment of Hepatitis C Audrey Broyer, Pharm D, CGP Clinical Pharm acy Specialist Manchester VA Medical Center Disclosure Statement I have no relevant financial relationships that would
More informationA Cure is Within Reach:
A Cure is Within Reach: A Review of the New HCV Medications Misty Miller, Pharm.D., BCPS, AAHIVP Clinical Assistant Professor University of Oklahoma College of Pharmacy September 11, 2015 Pre Assessment
More informationApplicable Coding: GCN: Solvaldi - 35708; Harvoni 037179; Viekira Pak 037614; Daklinza 037073, 037074; Technivie - 037844
Policy Subject: Policy Number: Classification: Hepatitis C Agents (new) SHS PBD38 Anti-virals: Hepatitis C Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS
More informationNew IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
More informationHepatitis Update. HCV Cure As A Paradigm for Convergence of Interests. Evidence Based Nuts and Bolts For the Family Doc 11/5/2014
Evidence Based Nuts and Bolts For the Family Doc Hepatitis Update William Carey MD MACG, FAASLD Oct 25, 2014 HCV Cure As A Paradigm for Convergence of Interests Hepatitis C Cure 1 Get Ready Get SET Go
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals (2015) Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationNEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationHepatitis C in 2015. Primary Care Providers: Linkage to Care
Hepatitis C in 2015 Primary Care Providers: Linkage to Care Michael D Voigt Medical Director, Liver Failure and Transplantation University of Iowa, Hospitals and Clinics Disclosures I have NO disclosures
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationNHS GRAMPIAN. Community Pharmacy Supply Of Hepatitis C Treatments. Pharmaceutical Care Information Pack
NHS GRAMPIAN Community Pharmacy Supply Of Hepatitis C Treatments Pharmaceutical Care Information Pack NHS Grampian Hepatology Team April 2015 NHS GRAMPIAN Community Pharmacy Supply Of Hepatitis C Treatments
More informationPRIOR AUTHORIZATION POLICY
PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus
More informationA Proposal for Managing the Harvoni Wave June 22, 2015
A Proposal for Managing the Harvoni Wave June 22, 2015 Clinical Background Hepatitis C is an infectious disease caused by the Hepatitis C Virus (HCV) that damages the liver over time. The disease affects
More informationDisclosure. Pharmacy technician objectives. Pharmacist objectives. Epidemiology. Terminology 3/3/2015. Treatment of Hepatitis C
Disclosure Treatment of Hepatitis C Katerina Tagaras PGY-1 Resident Palmetto General Hospital I do not have a vested interest in or affiliation with any corporate organization offering financial support
More informationThe question and answer session is not available after the live webinar.
1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments
More informationUpdates in Hepatitis C Treatment 2015
Disclosure Updates in Hepatitis C Treatment 2015 Lindsey Childs Kean, PharmD, MPH, BCPS Clinical Assistant Professor Department of Pharmacotherapy and Translational Research University of Florida College
More informationChronic Hepatitis C Virus (Chronic HCV)
Chronic Hepatitis C Virus (Chronic HCV) Amie Baumgartner PA-C Fall 2015 Purpose of Lecture! Educate Gastroenterology nurses about Hepatitis C and its treatment in order to improve their knowledge and confidence
More informationLedipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C
Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C Policy Number: Original Effective Date: MM.04.034 12/1/2014 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/1/2014
More informationEmerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV
More informationReview: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
More informationThe Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection
The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection A Technology Assessment Final Report April 15, 2014 Completed by: Institute
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationHEPATITIS C DISCUSSION GUIDE:
HEPATITIS C DISCUSSION GUIDE: INFORMATION AND ANSWERS TO AID YOUR COUNSELING OF PATIENTS INDICATION HARVONI is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. Warnings
More informationHepatitis C: Increasing Access and Improving Cure Rates
Hepatitis C: Increasing Access and Improving Cure Rates David Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine 1 Disclosures The planners and presenter have disclosed
More informationHepatitis C Virus (HCV)
HFS Report to Legislative Task Force Hepatitis C Arvind Goyal MD, MPH, MBA Medical Director Illinois Department of Healthcare and Family Services Hepatitis C Virus (HCV) Slowly progressive disease 40 years-median
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Interferon,
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationDaclatasvir (Daklinza)
FACTSHEET Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in
More informationUPDATE ON NEW HEPATITIS C MEDICINES
UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir
More informationPrior Authorization Policy
Prior Authorization Policy http://www.paramounthealthcare.com/providers Ribavirin Rebetol (ribavirin capsule or oral solution) Copegus (ribavirin tablet), Moderiba (ribavirin tablet), Ribasphere (ribavirin
More informationDebate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities
Debate: To Treat Now or Not to Treat Now Age, Disease Stage, Resistance, and Comorbidities Moderator: Raymond T. Chung, MD Associate Professor of Medicine, Harvard Medical School Director of Hepatology
More informationIntroduction. Background
INFORMATION DRIVES SOUND ANALYSIS, INSIGHT PHARMACY BENEFIT ADVISORY Introduction According to the Centers for Disease Control and Prevention (CDC), the rate of new hepatitis C virus (HCV) infections in
More informationHEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015
CME ACCREDITED INTERACTIVE TRAINING SESSION: HEPATITIS C (HCV) @DDW 2015 LIVER DISEASE 905 891 1900 www.careeducation.ca info@careeducation.ca Community Academic Research Education @wearecare CME ACCREDITED
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationDrug Interactions in Managing HIV/HCV Co-Infection Presenter: Christopher Keeys, Pharm.D., BCPS 28 October 2015
Drug Interactions in Managing HIV/HCV Co-Infection Presenter: Christopher Keeys, Pharm.D., BCPS 28 October 2015 Drug-Drug Interactions between Direct Acting Antiviral (DAA) and Antiretroviral Therapy (ART)
More informationUnderstanding the Reimbursement Environment in Hepatitis C
Understanding the Reimbursement Environment in Hepatitis C Camilla S. Graham, MD, MPH, Division of Infectious Diseases, Beth Israel Deaconess Medical Center Robert Greenwald, JD, Clinical Professor of
More informationHepatitis B: Objectives. Hepatitis C: Objectives. Hepatitis B: Natural History. Hepatitis B is a DNA virus and is NOT curable.
Two Silent Epidemics - Chronic Hepatitis B and Hepatitis C: A Primer for Primary Care Practitioners Rebekah Hamner, MA, MSN, APRN, AGCNS Austin Hepatitis Center Dr. Imtiaz Alam 1/25/15 Hepatitis B: Objectives
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationHIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
More informationHarvoni (Ledipasvir/Sofosbuvir) Treatment Agreement
Harvoni (Ledipasvir/Sofosbuvir) Treatment Agreement Liver Disease & Hepatitis Program Providers: Brian McMahon, MD; Youssef Barbour, MD; Lisa Townshend-Bulson, FNP-C; Annette Hewitt, FNP-C; Prabhu Gounder,
More informationUPDATE: New Hepatitis C Combination Agents
UPDATE: New Hepatitis C Combination Agents Ledipasvir and Sofosbuvir (Harvoni ) Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir (Viekira Pak ) Final Report July 2015 Review prepared by: Melissa Archer,
More informationSovaldi (sofosbuvir) Prior Authorization Criteria
INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationGUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF
NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR
More informationAn Action Guide for the Treatment of Chronic Hepatitis C Infection: Next Steps for Patients
The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection An Action Guide for the Treatment of Chronic Hepatitis C Infection: Next
More informationI. What s New and Updates/Changes (Last updated: February 17, 2015; last reviewed: February 17, 2015) Summary Table
Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health Contents I. What
More informationNew All Oral Therapy for Chronic Hepatitis C Virus (HCV): A Cost-Benefit Analysis
New All Oral Therapy for Chronic Hepatitis C Virus (HCV): A Cost-Benefit Analysis Jennifer Orsi, MPH 4 th International Conference on Viral Hepatitis March 17, 2014 2014 Walgreen Co. All rights reserved.
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365
Ombitasvir paritaprevir ritonavir with or without dasabuvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365 NICE 2015. All rights reserved.
More informationHCV Pipeline: The Next 18 Months Michael W. Fried, MD
HCV Pipeline: The Next 18 Months Michael W. Fried, MD Professor of Medicine Director, UNC Liver Center University of North Carolina at Chapel Hill Michael W. Fried, MD Commercial Disclosures Grants/Research
More informationAntiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)
Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).
More informationObjectives. Disclosures 1/26/2016. Which of These Drugs is FDA Approved for the Treatment of Genotype 1 Infection?
New Horizons: Navigating the Changing Tides of Hepatitis C Therapy Jennifer Andres, PharmD, BCPS Clinical Assistant Professor of Pharmacy Practice Temple University School of Pharmacy Objectives Review
More informationDrug Interactions in HIV/HCV coinfection
HIV/HCV Drug Interactions Case Based Discussion John J. Faragon, PharmD, BCPS, AAHIVP Regional Pharmacy Director, NY/NJ AETC HIV Pharmacist, Albany Medical Center 1 Drug Interactions in HIV/HCV coinfection
More informationTreatment of Chronic Hepatitis C - September 2015 Update
Treatment of Chronic Hepatitis C - September 2015 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Beat Müllhaupt, Andri Rauch, Jan Fehr and Darius
More informationTreatment of Chronic Hepatitis C - September 2014 Update
Treatment of Chronic Hepatitis C - September 014 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Darius Moradpour, Andri Rauch, Jan Fehr and Beat
More informationViral Hepatitis Prevention Board Meeting November 2013. The Netherlands: Hepatitis C treatment guidelines
Viral Hepatitis Prevention Board Meeting November 2013 The Netherlands: Hepatitis C treatment guidelines Floor Berden MD, PhD student Radboud university medical center Nijmegen, the Netherlands Conflicts
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationHEPATITIS C TREATMENT GUIDELINES
HEPATITIS C TREATMENT GUIDELINES Updated May 21, 2014 INSTRUCTIONS: 1. Review the posted Hepatitis C Treatment Guidelines document to validate that your patient meets the criteria for treatment. 2. Complete
More informationHepatitis C Virus and HIV Co-infection 2015 Update. Mia N. Barnes, Pharm.D., BCPS HIV CPE Training Program for Pharmacists February 8, 2015
Hepatitis C Virus and HIV Co-infection 2015 Update Mia N. Barnes, Pharm.D., BCPS HIV CPE Training Program for Pharmacists February 8, 2015 1 Statement of Disclosure Presenter has no relevant financial
More informationHepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
More informationNew Research On Direct-acting Antivirals For The Treatment Of Hepatitis C
New Research On Direct-acting Antivirals For The Treatment Of Hepatitis C Highlights From EASL 214, London, U.K. This report contains highlights from a selection of abstracts and posters presented during
More informationRobert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
More informationFederal Government Standing Committee on Health
Federal Government Standing Committee on Health Inquiry into Hepatitis C in Australia Professor Gregory Dore Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Australia Infectious
More informationPRACTICE GUIDANCE Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus
PRACTICE GUIDANCE Hepatitis C Guidance: AASLD-IDSA s for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus AASLD/IDSA HCV Guidance Panel* Preamble The pace of hepatitis C virus (HCV)
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364
Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2015. All rights reserved. Contents 1 Guidance... 3 Table 1 Daclatasvir
More informationDisclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
More informationHepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form
Hepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form For assistance, please call 1-855-552-6028 or fax completed form to 570-271-5610. Medical documentation may be requested. This
More informationObjectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening
Objectives Hepatitis C: The new era of screening and treatment David Crabb, M.D. Department of Medicine, Indiana University and Eskenazi Health Describe the natural history of HCV infection Be able to
More informationA 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
More informationCurrent Opinion in Hepatitis C Treatment
White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University
More informationThe Walgreens Connected Care SM hepatitis C program: a partnership in putting the patient first
The Walgreens Connected Care SM hepatitis C program: a partnership in putting the patient first November 2014 Glen Pietrandoni, RPh, AAHIVP, Walgreens Senior Director, Specialty Products and Services,
More informationHCV Treatment Failure
بسم االله الرحمن الرحيم HCV Treatment Failure Gamal Esmat PROF.OF HEPATOLOGY&TROPICAL MEDICINE CAIRO UNIVERSITY Director of Viral Hepatitis Treatment Centers (VHTCs( VHTCs) MOH-EGYPT www.gamalesmat.com
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationChronische Hepatitis C. 170 Millionen
Chronische Hepatitis C 170 Millionen Natürliche Geschichte der Hepatitis C Akute Hepatitis C Chronische Hepatitis C Hepatitis Zirrhose Clearance Zeit (20 Jahre) ist sehr unterschiedlich (Host, Virus, Umwelt)
More informationHCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
More informationDRUG INTERACTIONS WITH NEW/INVESTIGATIONAL HEPATITIS C NS5A INHIBITORS. Ledipasvir (LDV, GS-5885) Gilead. 90 mg once daily
DRUG INTERACTIONS WITH NEW/INVESTIGATIONAL HEPATITIS C NS5A INHIBITORS Pharmacology Adult Dose NS5A replication complex inhibitor Approved in Japan and the EU: 60 mg once daily NS5A inhibitor NS5A inhibitor
More informationNewton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP
Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP I do not have any relevant financial relationships with any commercial interests. At the end of
More informationNews Release. FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 (908) 740-1898
News Release FOR IMMEDIATE RELEASE Media Contact: Annick Robinson (438) 837-2550 Investor Contact: Amy Klug (908) 740-1898 Merck Receives Approval of ZEPATIER (elbasvir/grazoprevir) in Canada for the Treatment
More informationHepatitis C Infection In Singapore
Hepatitis C Infection In Singapore Richard Guan MBBS, MRCP(UK), FAMS(Gastro), FRCP(Edin), FRCP(Lond) Gastroenterologist & Hepatologist, Mt Elizabeth Medical Centre, Singapore Summary of HCV treatment practice
More informationHepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015
Hepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015 Disclosures: In the past two years I have participated in research 1 or received consultation/speaking fees 2 from: Astellas 2 Abbvie
More informationEvaluation and Prognosis of Patients with Cirrhosis
Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded
More informationHepatitis C: Increasing Access and Improving Cure Rates
Hepatitis C: Increasing Access and Improving Cure Rates David Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Disclosures The planners and presenter have disclosed
More informationHepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL
Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment
More informationHepatitis C Virus Infection in Massachusetts: A tale of two epidemics
Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics Daniel Church, MPH Massachusetts Department of Public Health Bureau of Infectious Disease 1 Goals of presentation Provide an overview
More informationHEPATITIS C UPDATE: A Quarter-Century Dramatic Journey. Steve T. Chen M.D. FACP, FACG
HEPATITIS C UPDATE: A Quarter-Century Dramatic Journey Steve T. Chen M.D. FACP, FACG Hepatitis C Virus: Morphology and Characteristics Hepatitis C Virus Discovered in 1989 Nucleic Acid: 9.6 kb ssrna 40-60
More informationTreatment of Hepatitis C in Patients with Renal Insufficiency
HEPATITIS WEB STUDY HEPATITIS C ONLINE Treatment of Hepatitis C in Patients with Renal Insufficiency Robert G. Gish MD Professor Consultant, Stanford University Medical Center Senior Medical Director,
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More information